Current Clinical Trials
LOKON001 (NCT02705196): Sponsor: Lokon Pharma, Phase I/IIa trial evaluating safety of LOAd703, an armed oncolytic adenovirus for pancreatic cancer. US Trial.
CAR:003 (NCT03068416): Sponsor Uppsala University, Phase II trial using CAR T cells and gemcitabine conditioning for B cell malignancy. Swedish trial.
LOKON002 (NCT03225989): Sponsor: Lokon Pharma, Phase I/II trial investigating safety of LOAd703 for solid malignancies including pancreatic cancer, biliary cancer, colorectal cancer and ovarian cancer. Swedish trial.
LOKON003 (NCT04123470): Sponsor: Lokon Pharma, Phase I/II trial combining LOAd703 with checkpoint inhibitor in malignant melanoma. US and Swedish trial.
MORPHEUS-CRS (NCT03555149): Sponsor Hoffmann-La Roche. Phase I/II trial evaluating atezolizumab in combination with different cancer therapeutics, including LOAd703 in patients with colorectal cancer. International trial.
Previous Clinical Trials
001:CD40L (NCT00891748): Sponsor: Uppsala University. AdCD40L Phase I/IIa trial enrolling patients with bladder cancer. Swedish trial.
- Malmström PU et al. Clin Cancer Res. 2010. 16:3279.
002:CD40L (NCT1455259): Sponsor: Uppsala University. AdCD40L Phase I/II trial enrolling patients with melanoma and other solid malignancies. Swedish trial.
- Irenaeus S et al. Cancer Gene Ther 2020. Epub ahead of print.
- Schitza A et al. Sci Rep. 2019. 9:18069.
- Irenaeus S et al. Oncotarget. 2017. 8:78573.
- Schitza A et al. J Transl Med 2017. 15:79.
- Loskog A et al. Br J Cancer. 2016. 114:872.
CAR:002 (NCT02132624): Sponsor: Uppsala University, Phase II trial using CAR T cells for B cell malignancy. Swedish trial.
- Enblad G et al. Clin Cancer Res. 2018. 24:6185.
RepoMeb (NCT03628079): Sponsor: Repos Pharma, Phase I/II trial investigating MBZ in colorectal cancer. Swedish trial.
- Mansoori S et al. Sci Rep. 2021. 11:8981.
VLX600 (NCT02222363): Sponsor Vivolux AB. Phase I trial investigating the safety of VLX600 in solid malignancies. US trial.
- Mody K et al. Invest New Drugs. 2019. 37:684.
VLX1570 (NCT02372240): Sponsor Vivolux AB. Phase I/II trial investigating the safety and efficacy of VLX1570 in multiple myeloma. US trial.
- Rowinsky E et al. Invest New Drugs. 2020. 38:1448.
Clinical Investigations
TRINITY: Data collection study to understand the response rate of gemcitabine and nab-paclitaxel in a defined subpopulation of pancreatic cancer patients in Sweden. (ongoing)
NORDIC CML SG: Investigation of plasma proteomics and immune profile before and after tyrosine kinase inhibitor therapy in chronic myeloid leukemia.
- Söderlund S et al. Leuk Res. 2016. 50:95.
- Christiansson L et al. Mol Cancer Res. 2015. 14:1181.
- Christiansson L et al. EUPA Open Proteomics. 2014. 3:37.
- Christiansson L et al. PLoS One. 2013, 8e55818.
PANCA: Investigation of immune profile pre and post gemcitabine treatment in pancreatic cancer.
- Eriksson E et al. J Transl Med. 2016.14:282.
Treatment of Dog Patients
CD40L:Dog. AdCD40L treatment of dog patients with melanoma. Swedish study.
- von Euler H et al. J Immunother. 2008. 3:377.
- Westberg S et al. J Immunother. 2013. 36:350.
- Saellström S et al. Front Vet Sci. 2021. In Press.
